CBLB and T-cell non-Hodgkin lymphoma: The enhanced antitumor responses of Cbl-b−/− mice have been documented in tumor models of EL4 (11), EG.7 (10), TC-1 (4, 9), UVB-induced skin tumor (9), and ATM-deficiency-induced T cell lymphoma (10).